All In MedTech

FDA Clearance Tracker · P160029

HeartStart OnSite Defibrillator (Model M5066A) and HeartStart Home Defibrillator (Model M5068A)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Jun 6, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jun 6, 2019

Approved

Time to decision

1,042 days

Received Jul 29, 2016. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P160029
Device name
HeartStart OnSite Defibrillator (Model M5066A) and HeartStart Home Defibrillator (Model M5068A)
Applicant location
Bothell, WA
Received
Jul 29, 2016
Decided
Jun 6, 2019
Decision
Approved
Supplements
26 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 870.5310

Every decision under product code NSA

FDA's approval statement

As written in FDA's record.

Approval for the HeartStart OnSite Defibrillator (Model M5066A) and HeartStart Home Defibrillator (Model M5068A). The HeartStart OnSite Defibrillator (M5066A) is indicated for use on potential victims of sudden cardiac arrest with the following symptoms:1) Unconsciousness; and 2) Absence of normal breathing.The HeartStart OnSite (Model M5066A) is indicated for adults over 55 pounds (25 kg). It is also indicated for infants and children under 55 lbs (25 kg) or 8 years old when used with the optional infant/child SMART pads. If Infant/Child SMART pads are not available, or you are uncertain of the childs age or weight, proceed with treatment using adult SMART pads.The HeartStart Home Defibrillator (M5068A) is indicated for use on potential victims of cardiac arrest with the following symptoms: 1) Unconsciousness; and 2) Absence of normal breathing. The HeartStart Home (M5068A) is indicated for adults over 55 pounds (25 kg). They are also indicated for infants and children under 55 lbs (25 kg) or 8 years old when used with the optional infant/child SMART pads. If Infant/Child SMART pads are not available, or you are uncertain of the childs age or weight, proceed with treatment using adult SMART pads.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NSA. The earliest in FDA's data is K040904, decided Sep 16, 2004.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Philips Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.